Umbilical cord blood (UCB) has received increasing attention as a source of unrelated hematopoietic stem cells for transplantation. Lysosomal diseases have been effectively treated and normal enzymatic activity has occurred subsequent to engraftment using UCB. The use of donor cells with normal amounts of enzyme, rather than those from carriers whose level may be 50% or less, is an obvious goal. The frequency of such heterozygotes varies from 1:10 to 1:140 or lower depending upon the disease at issue. We assayed the levels of lysosomal enzymes in normal UCB in random samples as well as those used for transplantation. We measured the following enzymatic activities: ␣-l-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy) and arylsulfatase A (metachromatic leukodystrophy). For the latter, levels of activity in UCB are comparable to those found in adult blood. In the case of arylsulfatase B (Maroteaux-Lamy) a level lower than adult level was found. An informed choice by the transplanting physician based on the activity of the relevant enzyme in the UCB donor will provide a better opportunity for an improved prognosis for more complete correction of the recipient's primary disease. Bone Marrow Transplantation (2000) 25, 541-544.
Summary:
Umbilical cord blood (UCB) has received increasing attention as a source of unrelated hematopoietic stem cells for transplantation. Lysosomal diseases have been effectively treated and normal enzymatic activity has occurred subsequent to engraftment using UCB. The use of donor cells with normal amounts of enzyme, rather than those from carriers whose level may be 50% or less, is an obvious goal. The frequency of such heterozygotes varies from 1:10 to 1:140 or lower depending upon the disease at issue. We assayed the levels of lysosomal enzymes in normal UCB in random samples as well as those used for transplantation. We measured the following enzymatic activities: ␣-l-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy) and arylsulfatase A (metachromatic leukodystrophy). For the latter, levels of activity in UCB are comparable to those found in adult blood. In the case of arylsulfatase B (Maroteaux-Lamy) a level lower than adult level was found. An informed choice by the transplanting physician based on the activity of the relevant enzyme in the UCB donor will provide a better opportunity for an improved prognosis for more complete correction of the recipient's primary disease. Bone Marrow Transplantation (2000) 25, 541-544. Keywords: cord blood; lysosomal enzyme activities Outcomes among 562 recipients of UCB transplants from unrelated donors have demonstrated the usefulness of this source of allogeneic hematopoietic stem cells. 1 More than 50 patients with lysosomal diseases have been successfully engrafted following use of unrelated UCB.
2 Engraftment data have included reconstitution of the specific deficient enzymatic activity. Graft-versus-host disease is considerably less than that noted from use of adult marrow donors. This provides the ability to use UCB when there is greater HLA disparity. [3] [4] [5] Engraftment and event-free survival data reported to date have been equivalent to that produced from matched unrelated adult marrow and non-identical sibling/ family matches.
Banked unrelated UCB provides a marked advantage because of the ready availability of donor cells. This ability to begin the transplant process rapidly can be of major importance compared to the time required for adult marrow volunteer procurement. This is of special importance when considering infants with globoid cell leukodystrophy in whom the disease progresses quite aggressively within weeks. 6 The relative absence of family history and clinical observations, when using UCB, provides less information than that readily obtained from adult unrelated and sibling/ related donors. In the latter instances, we have routinely measured the donor's enzyme level, to avoid unwitting use of a carrier (heterozygote). This unfortunate choice of donor could reduce the level in the recipient to potentially inadequate corrective ability. Such incomplete reconstitution of the enzyme activity has resulted in lessened improvement of the central nervous system status for diseases so treated. 7 Thus, the need for determining the activity of the relevant enzyme in the UCB donor is critical for providing assurance that efficacious levels of enzyme activity following engraftment is a realistic goal.
Since there has been no prior knowledge regarding the levels of activity of lysosomal enzymes in UCB leukocytes, the decision was made to test ␣-l-iduronidase, galactocerebrosidase, and arylsulfatases A and B. The rationale for the present study was to provide a set of values that could be used as reference for future determination of these activities in cord blood samples to be used for transplant.
Materials and methods

Preparation of leukocytes
Normal UCB was collected at delivery and cryopreserved in the standard manner. UCB specimens were obtained from the Placental Blood Program at the New York Blood Center and processed as described at the time of delivery. 1 Briefly, the red blood cells were depleted using Hespan (hetastarch) sedimentation at a 1:5 dilution, the volume reduced and the white blood cells cryopreserved in 10% DMSO in the standard manner. Several individual pellets obtained were separately cryopreserved and later used as a source of leukocytes for the enzymatic analysis. To prepare leukocytes, the frozen samples were thawed on ice, diluted with two volumes of 0.9% NaCl (saline solution) and centrifuged at 7700 g for 10 min. The supernatant was carefully removed and the pellets were washed twice more with saline solution.
The adult leukocytes were obtained from normal volunteers, separated by centrifugation and were frozen with and without DMSO and prepared exactly as above for cord blood.
Determination of enzyme activities
The activities of the lysosomal hydrolases ␣-l-iduronidase (Hurler MPS I-H), galactocerebrosidase (globoid cell leukodystrophy), arylsulfatase A (metachromatic leukodystrophy), and arylsulfatase B (Maroteaux-Lamy MPS VI) were determined in cord blood leukocyte according to well established assays. [8] [9] [10] [11] Leukocyte samples from normal adult blood were analyzed simultaneously with cord blood samples for direct comparison and quality control.
The cord blood specimens were random specimens tested to determine the normal range of activity for the enzymes under study. Those actually used for transplantation are included separately.
Results
To facilitate evaluation and comparisons, the activity ranges for the two groups of cord bloods (random and transplant) are separately reported. The activities reported for adult leukocytes are data generated by assays run in parallel with the cord blood specimens. The activity data are described as nmoles of substrate hydolyzed/h of incubation/mg leukocyte protein (nmol/h/mg protein) ( Table 1) .
␣-l-iduronidase
Activities are indicated in Table 1 . The mean and s.d. of cord blood leukocyte levels was 47 ± 13 in random samples and 53 ± 25 in the cord bloods used in transplantation. Under the same conditions the activity in adult leukocytes was 42 ± 6 (n = 6) Since the activity of ␣-l-iduronidase in cord blood is comparable to adult leukocytes, it is reasonable to expect that carrier levels in cord blood should fall in the same range as those reported for adult blood (13 Ϯ 5). Therefore, we can conclude that the activities of ␣-liduronidase in the samples used for transplant were within the normal range. The potential for ␣-l-iduronidase pseudodeficiency, although a rare event, should be kept in mind when testing for this enzyme for donor acceptability. 12 
Galactocerebrosidase
Activities of galactocerebrosidase are indicated in Table 1 . The activities in random cord blood specimens were found to be 3.1 Ϯ 1.4. The corresponding value for adult blood is 3.2 Ϯ 1.5. The range of galactocerebrosidase activity in cord blood used for transplant was 2.2 Ϯ 1.3. No significant differences between adult and cord blood values were found. However, it is important to note that there is a bimodal distribution of galactocerebrosidase enzyme activity. The higher normal levels are 4-12 and the lower normal levels range from 0.9-1.3. The lower normal range can overlap with the carrier range. 13 This makes it difficult to determine the carrier status of a random sample based solely on enzyme determination. Therefore, to differentiate between low normal and carrier, mutation analysis of the galactocerebrosidase gene will be necessary. 14 Given the choice among more than one matched sample for transplant, one may be able to select the cord blood with highest activity. Thus several samples should be studied rather than relying on one which unknowingly may be a carrier.
Arylsulfatase A
Activities of arylsulfatase A are indicated in Table 1 . Adult levels were found to be 86 ± 13 (n = 4). The activity was 64 ± 13 in random cord blood specimens and 86 ± 14 in the samples used in transplants. For this enzyme, the range of activity in cord blood is comparable to that of adult blood. Carrier levels are reported to be 43 ± 4. However, in the case of arylsulfatase A an additional complication is present. There is a frequency of pseudodeficiency in the general population of about 10-15%. Therefore, it would not be uncommon to find cord blood specimens with low arylsulfatase A activity. 15 
Arylsulfatase B
Activities of arylsulfatase B are shown in Table 1 . The levels for adult blood are reported to be 182 Ϯ 52, while carrier levels are reported to be 142 ± 37. The activity of the adult sample analyzed was 185, while under the same conditions the activity of seven random cord blood specimens was 78 ± 14.
Discussion
This is the first attempt to determine the normal levels of four lysosomal enzymes (␣-l-iduronidase, galactocerebrosidase, arylsulfatases A and B) in UCB. Prior to this study, the assumption was that the activity of UCB would be equivalent to the activity of normal adults. This was true for three enzymes, namely ␣-l-iduronidase, galactocerebrosidase and arylsulfatase A.
In the case of arylsulfatase B, the activity in cryopreserved cord blood was found to be significantly lower than the average adult values. We have reason to believe that this loss of activity may be due to environmental factors, ie the preservation conditions, and does not reflect the enzyme level in the original donor. In one instance, before the present study was undertaken, the low levels of arylsulfatase B in the cord blood caused one of the authors (WK) serious concern. The consideration was that the activity in this cord blood could represent that of a carrier which led to the decision not to use this sample for transplant in the patient. The data presented suggest that the activity originally found was in the normal range for cryopreserved cord blood and most likely did not reflect a carrier status. In preliminary experiments we found that addition of 10% DMSO (the freezing agent normally added to cord blood) to the incubation mixture resulted in about 30% inhibition of the enzyme activity. One possibility is that residual DMSO present in the leukocyte preparation may artefactually reduce arylsulfatase B activity.
UCB specimens are available from blood banks without knowledge whether the donor is clinically affected or is a carrier for these particular disorders being treated. For those contemplating transplantation, it is important to be aware that the incidence of carriers would be about 1:140 for Hurler, globoid-cell leukodystrophy and Maroteaux-Lamy. All of these three are inherited in an autosomally recessive manner with a disease frequency about 1:60 000.
Special attention is needed for metachromatic leukodystrophy patients to be transplanted from cord blood (and equally from adult volunteer marrow or family members) because of the high incidence of pseudodeficiency, which can be present in as many as 10-15% of the normal population. Even though the pseudodeficient person is not affected with the disease, cord blood (or marrow) from such an individual may not be suitable for providing changes of the disease manifestations and should not be used. 16 For instance, the arylsulfatase A activity was not determined in an adult marrow donor prior to transplant for one patient.
Bone Marrow Transplantation
This random marrow donor was later determined to be homozygous for the arylsulfatase A pseudodeficiency allele. 16 The result of the latter transplantation indicated no positive response even though engraftment was complete. Therefore the conclusion reached for metachromatic leukodystrophy is to be aware that a potential donor may be pseudodeficient.
Given all the above considerations, even though the incidence of carriers for the above disorders is generally low (in both cord blood and adult marrow volunteer sources), the better part of appropriate transplantation planning should include enzyme data on the 'normal' donor. Therefore, integrating into the transplant system the knowledge of donor relative to enzyme level, although an extra challenge, will be beneficial for the long-term outcome of the recipient.
There are several other lysosomal storage diseases which are considered candidates for transplantation. These include Gaucher disease type III, Sly syndrome (MPS VII), Wolman disease (acid lipase deficiency), Niemann-Pick type B (sphingomyelinase deficiency). The same rationale should be applied to peroxisomal disorders such as adrenoleukodystrophy Seven individuals have had umbilical cord blood identification as effected by measuring plasma VLCFA. 17 The data on normal cord bloods, both male and female, has not been published as yet. To date there have been 12 patients transplanted with cord blood for ALD. 2 As more of these latter genetic diseases are transplanted, they too will require a study to determine the normal values of the respective enzyme in cord blood.
We continue to make progress in understanding the bone marrow transplantation process. This includes the failure of mesenchymal stem cells to be established in long-term engrafted patients. 18 We know that there are opportunities available for appropriate treatment of several genetic diseases. 19 We will need to follow-up on the long-term survivors in order to understand the implications of the clonogenic capacities of donation from cord blood, 20 as well as marrow donors.
In summary, transplanters should involve qualified laboratories early in the donor work-up process to determine the activity of the relevant enzyme activity being treated in these specific diseases.
